<DOC>
	<DOCNO>NCT00031096</DOCNO>
	<brief_summary>Comparison efficacy safety Azelaic Acid 15 % gel vehicle male female patient mild moderate acne . Qualified subject apply gel face twice day period 12 week . Subjects require return doctor 's office 5 visit .</brief_summary>
	<brief_title>Comparison Efficacy Safety Azelaic Acid 15 % Gel With Its Vehicle Subjects With Mild Moderate Acne</brief_title>
	<detailed_description>Acne common inflammatory skin condition characterize skin eruption around hair follicle . People acne pustule ( zit pimple ) , papule , whitehead blackhead , nodule , redness skin . Acne usually involve face shoulder , also involve chest , arm , leg . The purpose study evaluate safety effectiveness investigational gel contain active medication compare gel without active medication ( placebo vehicle ) subject mild moderate facial acne . This study initially post Berlex , Inc. Berlex , Inc. rename Bayer HealthCare Pharmaceuticals , Inc. Intendis Inc. , Bayer HealthCare company , sponsor trial .</detailed_description>
	<mesh_term>Acne Vulgaris</mesh_term>
	<mesh_term>Azelaic acid</mesh_term>
	<criteria>To include study MUST : Predominantly facial localization acne Mild moderate acne vulgaris characterize presence inflammatory papule and/or pustule , comedo ( whiteheads/blackheads ) , severity suitable treatment topical single therapy . minimum ten maximum fifty inflammatory papule and/or pustule facial area 10 100 comedo facial area 3 small nodule ( approx . 5 mm diameter ) facial area Male female patient Age great equal 12 year Ability willingness accept comply administration investigational drug 12 week comply require medical examination ( sign inform consent ) . To include study MUST NOT : Localization acne predominantly chest and/or back confine chest and/or back Sandpaper acne hundred small facial comedo Moderate severe acne require systemic therapy Multitude small nodule and/or multiple large nodule , cyst , polyporous comedo , drain sinus e.g . nodulocystic/conglobate acne Other skin condition might interfere acne diagnosis and/or evaluation ( facial psoriasis , seborrheic dermatitis , perioral dermatitis papulopustular rosacea ) Anticipated schedule hospitalization , e.g . surgery , study Female patient continuously use present brand oral contraceptive ( ) hormone therapy least 3 month Continuous concurrent use topical and/or systemic treatment affect acne History hypersensitivity ingredient trial drug Concurrent involvement another investigational study participation within 30 day prior start study You must take follow type treatment therapy prior admit study : Oral isotretinoin ( i.e . Accutane ) 6 month Ortho TriCyclen Estrostep 3 month Oral antibiotic ( i.e . tetracycline , erythromycin ) 4 week Systemic corticosteroid 4 week Systemic nonsteroidal antiinflammatory drug ( NSAIDs ) antiinflammatory dose 4 week Topical ( apply skin ) retinoid cream , ointment , gel 2 week Topical antibiotic ( i.e . tetracycline , erythromycin , clindamycin ) 2 week Topical corticosteroid topical nonsteroidal antiinflammatory ( NSAIDs ) drug 2 week Topical imidazole antimycotic 2 week Topical benzoyl peroxide ( BPO ) 2 week Topical overthecounter remedy acne ( salicylic acid ) 2 week If , may still qualify study follow washout period ( time body completely eliminate , get rid , medication ) . The study doctor evaluate whether anything else history may affect safety study interfere evaluation . He/she may therefore advise participate .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Acne Vulgaris</keyword>
	<keyword>Propionibacterium acne</keyword>
</DOC>